Introduction
============

Age-related macular degeneration (AMD) is a neurodegenerative disease that leads to visual impairment and accounts for half of all cases of registered blindness in Western individuals older than 65 years of age \[[@r1]-[@r14]\]. There are approximately eight million people in the United States with symptoms of early or intermediate AMD, of whom approximately one million will develop advanced AMD within the next five years \[[@r15]-[@r17]\]. AMD is estimated to affect about 50 million people worldwide \[[@r18]-[@r20]\], and an increase in aging populations makes AMD a significant public health concern and a major focus of research efforts ([National Advisory Council](http://www.nei.nih.gov/resources/strategicplans/plan.htm)).

AMD is a clinically heterogeneous and genetically complex disease, with multiple environmental and genetic risk factors involved \[[@r20]-[@r25]\]. While epidemiological studies have linked cigarette smoking, alcohol consumption, light exposure, diet, drugs, and high blood pressure to the risk of AMD \[[@r19],[@r23],[@r26]-[@r36]\], familial aggregation and twin studies \[[@r37]-[@r43]\] have suggested that genetic variation may also play an important role in the disease. Although AMD has been reported to be associated with genetic variations in the genes of adenosine-triphosphate (ATP)-binding transporter protein 4 \[[@r44]-[@r46]\], apolipoprotein E \[[@r47]-[@r52]\], excision-repair cross-complementing group 6 \[[@r53]\], fibulin 5 \[[@r54]\], fibulin 6 \[[@r55],[@r56]\], elongation of very-long-chain fatty acids-like 4 \[[@r57]-[@r59]\], factor B/complement component 2 \[[@r60]\], toll-like receptor 4 \[[@r61]-[@r63]\], and vascular endothelial growth factor \[[@r64]\], recent genome-wide linkage studies found that genomic regions at chromosomes 1q31--32 and 10q26 may have a bigger role in susceptibility to AMD \[[@r65]\]. The identification of overlapping loci on chromosome 1q by several study groups \[[@r66]-[@r68]\] indicates that this locus probably harbors a major AMD-associated gene. Recently, the component factor H (*CFH*) gene on chromosome 1q31 has been revealed as the first major AMD-susceptibility gene, perhaps accounting for about 30%--50% of AMD patients. The *CFH Y402H* variant in the *CFH* gene has also been identified as a causal polymorphism in studies of populations other than those of European and North American origin \[[@r30],[@r69]-[@r78]\], and a follow-up meta-analysis \[[@r79]\] has confirmed this association in Western populations. Studies in Japan, however, did not show any associations between *CFH Y402H* polymorphism and AMD \[[@r80],[@r81]\], suggesting that there must be some other loci susceptible for AMD. Several studies have showed that a locus at chromosome 10q26 \[[@r82]-[@r84]\] of *CFH* may independently contribute to AMD susceptibility \[[@r65],[@r76],[@r82]-[@r84]\]. Three genes identified at chromosome 10q26 and associated with the risk of AMD are Pleckstrin Homology Domain-containing Protein Family A member 1, age-related maculopathy susceptibility 2 (*LOC387715/age-related maculopathy susceptibility 2 \[ARMS2\]*), and high-temperature requirement factor A1 (*HTRA1/PRSS11*) \[[@r65],[@r76],[@r82]-[@r84]\]. Thus, AMD appears to be a product of the interaction between multiple loci of susceptibility rather than a collection of single-gene disorders. However, the number of loci involved, the degree of attributable risk conferred, and the interactions between various loci remain obscure.

The *HTRA1* gene spans a 53,366-base region on chromosome 10q26 (124211047--124264413, Gene ID: 5654); it encodes a member of a family of serine proteases expressed in both mouse and human retinas \[[@r85],[@r86]\], and its expression in human fibroblasts increases with aging \[[@r87]\]. HTRA1 appears to regulate the degradation of extracellular matrix proteoglycans. This activity has been considered to facilitate access of other degradative matrix enzymes, such as collagenases and matrix metalloproteinases, to their substrates \[[@r88]\]. Overexpression of HTRA1 alters the integrity of Bruch's membrane, favoring the invasion of choroid capillaries across the extracellular matrix, as occurs in wet AMD. HTRA1 also binds and inhibits transforming growth factor-β (TGF-β), an important regulator of extracellular matrix deposition and angiogenesis \[[@r89]\]. During the years 2006 to 2008, several studies were conducted to investigate the association between HTRA1 gene polymorphisms and AMD. A single-nucleotide polymorphism ([rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638)) in the promoter region of the HTRA1 gene was found to be significantly associated with susceptibility to AMD in studies of Caucasian populations in the US \[[@r90]-[@r97]\], Central Europe \[[@r98]\], France \[[@r99]\], and the UK \[[@r100]\]; of East Asian populations in China \[[@r101]-[@r104]\] and Japan \[[@r105]-[@r107]\]; and of Indian populations in India \[[@r108]\]. Another putative AMD-susceptibility gene, *LOC387715/ARMS2*, has recently been identified. *LOC387715/ARMS2* encodes a deduced 107--amino acid protein with nine predicted phosphorylation sites and a molecular mass of 12 kDa. Real-time (RT)-PCR analysis demonstrated that *LOC387715/ARMS2* transcripts were expressed in the retina and in a variety of other tissues and cell lines. Transfection experiments in mammalian cells localized the protein to the mitochondrial outer membrane \[[@r95]\]. Up to now, the biologic characterization of this gene has been limited. However, Rivera et al. \[[@r109]\] concluded that the A69S single-nucleotide polymorphism ([rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924)) in exon 1 of the *LOC387715/ARMS2* gene was the most likely susceptibility allele of AMD. Since an individual study may not have sufficient statistical robustness to confirm the association between *HTRA1* and *LOC387715/ARMS2* gene polymorphisms and AMD, we considered that a meta-analysis that combined data from all published studies would provide a more accurate estimate of the extent of association, leading to less risk of false-positive results \[[@r110]\]. Thus, we systematically pooled the results of all available population-based association studies of the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism, the *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism, and AMD. We attempted to estimate the strength of the genetic association with AMD, as well as the genetic mode of action, and to gauge the extent of heterogeneity in the strength of the associations among different studies.

Methods
=======

Search strategy and inclusion criteria
--------------------------------------

We searched the US National Library of Medicine's [PubMed](http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed), [Embase](http://www.embase.com/home), [OMIM](http://www.ncbi.nlm.nih.gov/omim/), [ISI Web of Science](http://apps.isiknowledge.com/UA_GeneralSearch_input.do?product=UA&search_mode=GeneralSearch&SID=3EodPa48Om2jnl83EAP&preferencesSaved=), and Chinese National Knowledge Infrastructure ([CNKI](http://www.cnki.net)) databases in a systematic manner to retrieve all genetic association studies on the *HTRA1* ([rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638)) and *LOC387715/ARMS2* ([rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924)) polymorphisms and AMD published before April 2008. The search strategy was based on a combination of the terms (HtrA serine peptidase 1 or *HTRA1*), (*age-related maculopathy susceptibility 2 or LOC387715*), and (age-related macular degeneration or AMD). The references of all computer-identified publications were searched for additional studies, and the PubMed option ''Related Articles'' was also used to search for potentially relevant papers. Searches were performed by two independent reviewers (B.Z. and J.Y.). We included all published articles regardless the language of publication.

Studies were included if they met the following criteria: 1) The study reported original data from case-control or cohort studies. 2) The alleles and genotypes for the *HTRA1* polymorphism ([rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638)), respectively, were A and G and AA, AG, and GG. 3) The alleles and genotypes for the *LOC387715/ARMS2* polymorphism ([rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924)), respectively, were G and T and GG, GT, and TT. 4) The numbers of subjects possessing each allele and genotype in the AMD and control groups were available. 5) In the case of multiple publications from the same study group, the most complete and recent results were used. We set no restriction on the source of controls (general population, clinic, or hospital). For those studies where AMD was graded (e.g., drusen, pigment abnormalities in retinal pigment epithelium \[RPE\], geographic atrophy, and choroidal neovascularization \[CNV\]), the gradings were combined into a single AMD group.

Data extraction
---------------

Data were extracted independently by two investigators (B.Z. and J.Y.), who used recommended guidelines to report on meta-analyses of observational studies \[[@r111]\]. The following data were extracted from the eligible studies: authors, journal title and year of publication, country of origin, selection and characteristics of cases and controls, demographic data, ethnicity of the study population (e.g., Caucasian or East Asian), numbers of eligible and genotyped cases and controls, and genotype distributions in cases, controls, and available subgroups. Furthermore, we examined whether matching had been used; whether there was specific mention of blinding of the genotyping personnel to the clinical status of subjects; whether the genotyping method used had been validated; and whether genotype frequencies in control groups conformed to the Hardy--Weinberg equilibrium (HWE). Any disagreement was adjudicated by a third author (R.L.).

Statistical analysis
--------------------

We used the odds ratio as the metric of choice and this was estimated for each study. To explore the possible association between *HTRA1* and *LOC387715/ARMS2* polymorphisms and AMD, and to avoid excessive comparisons, we calculated the odds ratio by two methods: allele comparison (the A allele versus the G allele in the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism), and comparing the risk-variant homozygotes and heterozygotes with wild homozygotes (i.e., AA versus GG \[*OR*~1~\] and AG versus GG \[*OR*~2~\] in the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism). We estimated and characterized the prevalence of the risk allele with only the data from controls. When we analyzed genotype data in the meta-analysis, zero cell counts were assigned a fixed value (typically 0.5). In addition, we calculated the population attributable risk (PAR) of the risk allele according to the Chang et al. \[[@r112]\] method.

We first compared the alleles for cases and controls to detect overall differences and genetic association. Allele frequencies were computed for studies reporting only genotypic data. Pooled odds ratios were computed two times: by the fixed effects model of Mantel and Haenszel \[[@r113]\], and by the random effects model of DerSimonian and Laird \[[@r114]\]. Random effects incorporated an estimate of between-study variance and provided wider confidence intervals when the results of the constituent studies differed. The random effects model was more appropriate when heterogeneity was present \[[@r115]\]. Unless otherwise stated, the random effects estimates reported here were calculated by the DerSimonian and Laird model.

Our primary genetic analysis of the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism, the *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G-to -T polymorphism, and AMD was based on the comparisons between risk-variant homozygotes and heterozygotes versus wild homozygotes so that the strength of the genetic association and the genetic mode of action could be identified exactly. Once an overall gene effect was confirmed, the genotype effects and genetic model were estimated by using the genetic model-free approach suggested by Minelli et al. \[[@r116]\], in which no assumptions about genetic models are required. A multivariate meta-analysis employing the Bayesian method \[[@r116]\] was used to calculate *OR*~1~ and *OR*~2~. The logarithm (log) odds ratios were modeled on the basis of both between- and within-study variations. A stochastic parameter lambda (λ), equal to the ratio of log *OR*~2~ and log *OR*~1~, was also computed \[[@r115]\]. The parameter λ suggested the genetic mode of action; specifically, the model is a recessive model if λ=0, a codominant model if λ=0.5, a dominant model if λ=1, and homozygous or heterosis model if λ\<0 or λ\>1.

We examined the deviations from the HWE in control populations for each study by using the exact method \[[@r117]\]. For all the analyses, we compared results between inclusion and exclusion of studies in Hardy--Weinberg (HW) disequilibrium. In addition, all studies were included regardless of HWE and provided a revision of the degree of HW disequilibrium by using the inbreeding coefficient (*F*) suggested by Trikalinos et al. \[[@r118]\]. In brief, data in the control group were used to assess the *F* value for each study. Predicted genotype frequencies were estimated and then used to replace the observed frequencies in the summary analysis of magnitude and the genetic model.

In sensitivity analysis, we estimated between-study heterogeneity across all eligible comparisons using Cochran's *Q* statistic \[[@r115]\]. We also reported the *I*^2^ statistic, which describes the percentage of variability in point estimates due to sample heterogeneity rather than sampling error \[[@r119],[@r120]\], and can quantify heterogeneity irrespective of the number of studies \[[@r120],[@r121]\]. *I*^2^ values larger than 75% were considered to represent a "notable" heterogeneity \[[@r120],[@r121]\]. Publication bias among studies was assessed by funnel plots \[[@r122]\] and cumulative meta-analysis \[[@r123]\]. In the analysis of subgroups, we estimated odds ratios according to racial descent (Caucasians versus East Asians) and AMD type (wet AMD and other subtype or combined AMD).

All analyses were conducted with Stata software, version 9.0 (StataCorp, 2005) \[[@r124]\], using the *meta, metan, metabias, metacum, and metareg* commands, except the Bayesian method of genotype-based analysis. We fitted the Bayesian models by using Markov chain Monte Carlo methods with a Bayesian framework and performed our inferences using WinBUGS 1.4.3 (Imperial College School of Medicine at St Mary\'s, London 2003) \[[@r125]\], taking advantage of its flexibility as well as its ability to incorporate full uncertainty across all unknown parameters. Bayesian analyses yielded credible intervals rather than confidence intervals; a 95% credible interval (*CrI*) describes a range in which it is probable that an unknown quantity lies within this interval. A "burn-in" of 10,000 iterations is performed for models, followed by 50,000 iterations for parameter estimates. A p value less than 0.05 was considered statistically significant.

Results
=======

Eligible studies
----------------

A total of 29 studies were identified based on our search strategies, of which 13 studies \[[@r95]-[@r106],[@r108]\] were eligible for inclusion in this meta-analysis; all of these were written in English. One \[[@r101]\] did not report genotype information in their paper, but online supporting materials provided the data. Two of the studies \[[@r100],[@r106]\] did not have genotypic data, but the authors kindly sent the supplementary information to us. Sixteen studies were ineligible for the following reasons: six were reviews \[[@r22],[@r24],[@r126]-[@r129]\], six did not study the association between the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism and AMD \[[@r92]-[@r94],[@r130]-[@r132]\], two \[[@r90],[@r91]\] were duplicated reports of the most recent and comprehensive one \[[@r97]\], and one did not have genotype data \[[@r107]\].

Detailed characteristics of the 13 included studies on the association between *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism and AMD are presented in [Table 1](#t1){ref-type="table"}. Among them, six studies related to Caucasian subjects, six to East Asians, and one to Indians. The average age of subjects ranged from 64.0 years to 81.2 years for cases and from 64.0 years to 77.4 years for controls. Characteristics of the 13 included studies on the association between *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism and AMD are presented in [Table 2](#t2){ref-type="table"}. Among them, 14 studies related to Caucasians, three to East Asians, and one to Indians. The average age ranged from 60 to 79 years for cases and from 60 to 77 years for controls. All of the eligible studies had case-control designs. Cases in the studies were recruited from hospital patients and controls were mainly healthy populations recruited from the hospital or community and unrelated to cases.

###### Characteristics of case-control studies included in a meta-analysis of the association between the *HTRA1* gene polymorphisms and AMD

  **Ref**       **Year**       **Region, country study was conducted**   **Ethnicity**   **Study design**   **Sex composition in cases (% males)**   **Mean age (years)**     **Cases**   **Controls**                                                              **Number of eligible subjects**                                                                                                                                                                
  ------------- -------------- ----------------------------------------- --------------- ------------------ ---------------------------------------- ------------------------ ----------- ------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----- -----
  **Cases**     **Controls**   **Cases**                                 **Controls**                                                                                                                                                                                                                                                                                                                                                                              
  \[[@r101]\]   2006           China                                     East Asian      Case-control       68                                       74.9                     74.2        Wet AMD                                                                   Age matched controls without AMD, confirmed by full ophthalmologic examination                                                                                                           96    130
  \[[@r98]\]    2007           Austria                                   Caucasian       Case-control       35.5                                     78                       77.4        Exudative AMD in AMD level 4                                              Caucasians without AMD on the base of a detailed eye examination and fundus examination                                                                                                  242   157
  \[[@r102]\]   2007           China                                     East Asian      Case-control       45.1                                     64.0/                    64          Drusen, and wet AMD                                                       Without any AMD, confirmed by a normal eye examination                                                                                                                                   164   106
  \[[@r105]\]   2007           Japan                                     East Asian      Case-control       72.4                                     71.9                     67.9        AMD, combined                                                             Without AMD and unrelated to cases, confirmed by full ophthalmologic examination                                                                                                         123   133
  \[[@r106]\]   2007           Japan                                     East Asian      Case-control       79.5                                     75.7                     71.2        Wet AMD                                                                   Hospital-based controls without retinal diseases and AMD on the base of full ophthalmologic examination                                                                                  73    94
  \[[@r95]\]    2007           USA                                       Caucasian       Case-control       NR                                       \>68.0                   \>68.0      AMD, combined                                                             Without AMD on the base of full ophthalmologic examination                                                                                                                               535   288
  \[[@r99]\]    2007           France                                    Caucasian       Case-control       NR                                       \>65.0                   \>65.0      Exudative AMD                                                             Without any type of drusen, geographic atrophy, or exudative AMD.                                                                                                                        200   116
  \[[@r96]\]    2007           USA                                       Caucasian       Case-control       NR                                       71.3                     72.8        Wet AMD                                                                   Without AMD on the base of full ophthalmologic examination                                                                                                                               134   134
  \[[@r100]\]   2007           UK                                        Caucasian       Case-control       40.6                                     \>65.0                   \>65.0      Wet AMD                                                                   Without AMD on the base of full ophthalmologic examination                                                                                                                               401   266
  \[[@r97]\]    2008           USA                                       Caucasian       Case-control       49.0/ 52.5/ 38.0/ 44.4                   81.2/ 78.9/ 81.0/ 78.3   74          bilateral wet AMD, unilateral wet AMD, bilateral GA, and unilateral GA.   Without any type of drusen, GA, AMD, and RPE                                                                                                                                             776   294
  \[[@r103]\]   2008           China                                     East Asian      Case-control       54                                       71.2                     71.5        Dry and wet AMD                                                           Age and sex matched controls without any visual impairment, excluded a family history of AMD and any type of drusen, geographic atrophy, CNV, or other retinal disorder in either eye.   95    90
  \[[@r104]\]   2008           China                                     East Asian      Case-control       54                                       75.5                     73.3        Exudative AMD                                                             Without any AMD and any other major eye diseases                                                                                                                                         163   183
  \[[@r108]\]   2008           India                                     Indian Asian    Case-control       NR                                       68.8                     64.4        AMD, combined                                                             Ethnic matched controls, without a family history of AMD or any other ocular or systemic diseases                                                                                        250   250

###### Characteristics of case-control studies included in a meta-analysis of the association between the *LOC387715* gene polymorphisms and AMD

  **Ref**       **Year**       **Region, country study was conducted**   **Ethnicity**   **Study design composition in cases (% males)**   **Sex**   **Mean age (years)**   **Cases**   **Controls**      **Number of eligible subjects**                                                                                 
  ------------- -------------- ----------------------------------------- --------------- ------------------------------------------------- --------- ---------------------- ----------- ----------------- --------------------------------------------------------------------------------------------------------- ----- ------
  **Cases**     **Controls**   **Cases**                                 **Controls**                                                                                                                                                                                                                                     
  \[[@r106]\]   2007           Japan                                     East Asian      Case-control                                      79.5      75.7                   71.2        Wet AMD           Hospital-based controls without retinal diseases and AMD on the base of full ophthalmologic examination   73    94
  \[[@r95]\]    2007           USA                                       Caucasian       Case-control                                      NR        \>68.0                 \>68.0      Wet AMD+Dry AMD   Without AMD on the base of full ophthalmologic examination                                                431   280
  \[[@r99]\]    2007           France                                    Caucasian       Case-control                                      NR        \>65.0                 \>65.0      Wet AMD           Without any type of drusen, geographic atrophy, or exudative AMD.                                         118   116
  \[[@r96]\]    2007           USA                                       Caucasian       Case-control                                      NR        71.3                   72.8        Wet AMD           Without AMD on the base of full ophthalmologic examination                                                134   134
  \[[@r100]\]   2007           UK                                        Caucasian       Case-control                                      40.6      \>65.0                 \>65.0      Wet AMD           Without AMD on the base of full ophthalmologic examination                                                401   266
  \[[@r108]\]   2008           India                                     Indian Asian    Case-control                                      NR        68.8                   64.4        Wet AMD+Dry AMD   Ethnic matched controls, without a family history of AMD or any other ocular or systemic diseases         193   203
  \[[@r3]\]     2008           China                                     East Asian      Case-control                                      58.7      66                     66.1        Wet AMD           Without any AMD and any other major eye diseases aside from mild age-related cataracts                    121   132
  \[[@r84]\]    2005           Germany                                   Caucasian       Case-control                                      NR        NR                     NR          Wet AMD+Dry AMD   Without any AMD and any other major eye diseases                                                          759   594
  \[[@r84]\]    2005           Germany                                   Caucasian       Case-control                                      35.1      75.01                  68.25       Wet AMD+Dry AMD   Unrelated controls without any AMD and any other major eye diseases                                       361   328
  \[[@r133]\]   2006           USA                                       Caucasian       Case-control                                      42        79.5                   76.5        Wet AMD+Dry AMD   Without AMD on the base of full ophthalmologic examination                                                693   172
  \[[@r133]\]   2006           USA                                       Mixed           Case-control                                      44        73.2                   70.3        Wet AMD+Dry AMD   Without AMD on the base of full ophthalmologic examination                                                120   995
  \[[@r56]\]    2007           Russia                                    Caucasian       Case-control                                      27.7      72.6                   71.1        Wet AMD+Dry AMD   Free of macular changes                                                                                   155   151
  ??            2007           Japan                                     East Asian      Case-control                                      70.5      73.4                   73.6        Wet AMD           Without any AMD                                                                                           95    99
  ??            2007           USA                                       Caucasian       Nested case-control                               35.2      60.1                   60.2        Wet AMD+Dry AMD   Within 1 year of the same age with cases, and underwent eye examination in the past 2 years               445   1041
  \[[@r128]\]   2007           USA                                       Caucasian       Case-control                                      42.6      79                     72          Wet AMD+Dry AMD   AMD free controls                                                                                         399   329
  \[[@r13]\]    2007           Australia                                 Caucasian       Cohort                                            39.9      75.6                   74.9        Wet AMD+Dry AMD   AMD free controls                                                                                         278   557
  \[[@r93]\]    2007           USA                                       Caucasian       Case-control                                      NR        NR                     NR          Wet AMD           Without any AMD                                                                                           87    232
  \[[@r83]\]    2008           USA                                       Caucasian       Case-control                                      39.6      79.1                   72.9        Wet AMD+Dry AMD   Without AMD on the base of full ophthalmologic examination                                                164   155

Allele comparison
-----------------

Data from the control groups were used to calculate the summary allele frequency. The frequency of the risk allele A in the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism among controls was 32.33% (95% confidence interval \[*CI*\]: 26.29, 38.38), and was significantly higher in Asians than in Caucasians (40.11% \[95% *CI*: 35.11, 45.12\] versus 23.25% \[95% *CI*: 18.41, 28.09\], p=0.0001). The frequency of the risk allele T in the *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism among controls was 25.17% (95% *CI*: 17.33, 33.00), and was also significantly higher in Asians than in Caucasians (38.67% \[95% *CI*: 34.63, 42.71\] versus 21.62% \[95% *CI*: 17.41, 28.83\], p=0.0000178).

All of the 13 studies were included to evaluate the association between the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism and AMD \[[@r95]-[@r106],[@r108]\]. As shown in [Figure 1A](#f1){ref-type="fig"}, individuals with the A allele experienced a 2.80-fold increased risk of AMD when compared to individuals with the G allele (random effect *OR*=2.910, 95% *CI*: 2.552, 3.318; *Q*=25.769, p=0.012, *I*^2^=53.4%). The magnitude of the effect was similar for Asians (random effect *OR*=2.841, 95% *CI*: 2.482, 3.252) and Caucasians (random effect *OR*=2.981, 95% *CI*: 2.357, 3.370). However, there was significantly greater between-study heterogeneity among Caucasians (*Q*=20.128, p=0.001, *I*^2^=75.2%) than Asians (*Q*=5.636, p=0.465, *I*^2^=0.0%). Excluding and adjusting two studies \[[@r96],[@r97]\] with Hardy--Weinberg equilibrium did not change the results (data not shown). After appropriately carrying out a set of prespecified subgroups \[[@r97]\], a low level of between-study heterogeneity was found (random effect *OR*=3.043, 95% *CI*: 2.725, 3.397; *Q*=14.318, p=0.216, *I*^2^=23.2%). We did not find any evidence of publication bias in the eligible studies (corrected Begg's test *z*=0.43, corrected p=0.669). [Figure 2](#f2){ref-type="fig"} shows the cumulative meta-analysis results; they remained significant and were consistent over time.

![Random-effects meta-analysis of allele (A versus G) of the HTRA1 gene [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism and age related macular degeneration (AMD). **A**: Results from random-effects meta-analysis of allele (A versus G) of the *HTRA1* gene [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism and AMD. **B**: Results of the random-effects meta-analysis of the allele (T versus G) of the *LOC387715/ARMS2* gene [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism and AMD. Reference numbers are given in parentheses. For study details, see [Table 1](#t1){ref-type="table"} and [Table 2](#t2){ref-type="table"}.](mv-v16-1958-f1){#f1}

![Cumulative random-effects meta-analysis of allele (A versus G) of the *HTRA1* gene [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism and age related macular degeneration (AMD). For study details, see [Table 3](#t3){ref-type="table"}.](mv-v16-1958-f2){#f2}

The association between the *LOC387715/ ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism and AMD was also evaluated. As shown in [Figure 1B](#f1){ref-type="fig"}, individuals with the T allele had a 2.734 fold increased risk of AMD when compared to individuals with the G allele (random effect *OR*=2.734, 95% *CI*: 2.366, 3.158; *Q*=80.195, p=0.000, *I*^2^=78.8%). The magnitude of the effect was similar between Asians (random effect *OR*=2.692, 95% *CI*: 2.086, 3.315) and Caucasians (random effect *OR*=2.794, 95% *CI*: 2.333, 3.346). There was also a significant difference between-study heterogeneity among Caucasians (*Q*=73.265, p=0.000, *I*^2^=83.6%) as opposed to Asians (*Q*=0.481, p=0.786, *I*^2^=0.0%). [Figure 3](#f3){ref-type="fig"} shows the cumulative meta-analysis results; they remained significant and were consistent over time.

![Cumulative random-effects meta-analysis of allele (G versus T) of the *LOC387715/ ARMS2* gene [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism and age related macular degeneration (AMD). For study details, see [Table 4](#t4){ref-type="table"}.](mv-v16-1958-f3){#f3}

Genotype comparison
-------------------

The genotype frequency of the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism between case and control groups is presented in [Table 3](#t3){ref-type="table"}. The genotype effects for AA versus GG (*OR*~1~) and AG versus GG (*OR*~2~) were calculated for each study. The genotype frequency of the *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism between the case and control groups is presented in [Table 4](#t4){ref-type="table"}. The genotype effects for TT versus GG (*OR*~1~) and TG versus GG (*OR*~2~) were calculated for each study.

###### The association between the *HTRA1* gene polymorphisms and AMD---- Allele and genotype frequencies of case-control studies included in a meta-analysis

  **Ref**        **Year**       **Genotype distribution**   **AA / GG**   **AG / GG**           **A / G**                                                                                                                                        
  -------------- -------------- --------------------------- ------------- --------------------- ----------- --------- -------- -------- --------------------- --------- ------------ --------- ---------------- -------- --------------- ------- --------------
  **cases**      **controls**                                                                                                                                                                                                                    
  **N**          **AA**         **AG**                      **GG**        **P value for HWE**   **N**       **AA**    **AG**   **GG**   **P value for HWE**   **OR1**   **95% CI**   **OR2**   **95% CI**       **OR**   **95% CI**              
  \[[@r101]\]    2006           96                          44            40                    18          0.266     130      14       59                    57        0.976        9.952     4.465\~22.184    2.147    1.104\~4.174    3.626   2.450\~5.368
  \[[@r98]\]     2007           242                         67            108                   67          0.247     157      8        50                    99        0.877        12.375    5.583\~27.432    3.192    2.022\~5.039    3.723   2.693\~5.158
  \[[@r102]\]    2007           164                         68            77                    19          0.924     106      15       63                    28        0.104        6.681     2.980\~14.979    1.801    0.921\~3.523    2.37    1.664\~3.375
  \[[@r105]\]    2007           123                         45            55                    26          0.488     133      22       57                    54        0.582        4.248     2.127\~8.487     2.004    1.103\~3.640    2.231   1.566\~3.178
  \[[@r106]\]    2007           73                          29            39                    5           0.239     94       16       40                    38        0.627        13.775    4.520\~41.984    7.41     2.642\~20.786   3.189   2.029\~5.013
  \[[@r95]\]     2007           457                         102           183                   172         \<0.001   280      11       90                    179       0.997        9.65      5.006\~18.601    2.112    1.525\~2.937    2.937   2.299\~3.753
  \[[@r99]\]     2007           118                         32            57                    29          0.937     116      5        41                    70        0.948        15.448    5.476\~43.582    3.356    1.860\~6.055    3.734   2.498\~5.583
  \[[@r96]\]\*   2007           134                         43            54                    37          0.0837    134      21       43                    70        0.0111       3.874     2.009\~7.469     2.376    1.350\~4.180    2.358   1.657\~3.347
  \[[@r100]\]    2007           401                         106           172                   123         0.019     266      6        91                    169       0.296        24.274    10.327\~57.057   2.597    1.841\~3.664    3.826   2.963\~4.942
  \[[@r97]\]\*   2008           776                         131           400                   245         0.327     294      10       128                   156       0.0282       8.341     4.253\~16.360    1.99     1.500\~2.640    2.042   1.652\~2.525
  \[[@r103]\]    2008           95                          53            33                    9           0.53      90       19       47                    24        0.903        7.439     2.940\~18.819    1.872    0.772\~4.541    3.046   1.973\~4.703
  \[[@r104]\]    2008           163                         94            51                    18          0.0379    183      38       90                    55        0.994        7.559     3.398\~14.509    1.732    0.919\~3.262    3.31    2.403\~4.559
  \[[@r108]\]    2008           229                         90            89                    50          0.0111    184      21       85                    78        0.956        6.686     3.695\~12.098    1.633    1.028\~2.595    2.701   2.033\~3.589
  Total                         3071                                                                                  2167                                                                                                                        

\* Hardy--Weinberg disequilibrium in case and/or control group

###### The association between the *LOC387715* gene polymorphisms and AMD---Allele and genotype frequencies of case-control studies included in a meta-analysis

  **Ref**       **Year**       **Genotype distribution**   **TT / GG**   **TG / GG**           **T / G**                                                                                                                                       
  ------------- -------------- --------------------------- ------------- --------------------- ----------- --------- -------- -------- --------------------- --------- ------------ --------- --------------- -------- --------------- ------- --------------
  **cases**     **controls**                                                                                                                                                                                                                   
  **N**         **TT**         **TG**                      **GG**        **P value for HWE**   **N**       **TT**    **TG**   **GG**   **P value for HWE**   **OR1**   **95% CI**   **OR2**   **95% CI**      **OR**   **95% CI**              
  \[[@r106]\]   2007           73                          27            40                    6           0.25      94       15       41                    38        0.783        11.4      3.920\~33.155   6.179    2.354\~16.217   2.979   1.901\~4.668
  \[[@r95]\]    2007           431                         133           180                   118         \<0.001   280      12       99                    169       0.992        15.875    8.405\~29.979   2.604    1.854\~3.658    3.809   2.995\~4.845
  \[[@r99]\]    2008           118                         37            55                    26          0.811     116      5        40                    71        0.978        20.208    7.169\~56.962   3.755    2.048\~6.886    4.388   2.928\~6.576
  \[[@r96]\]    2008           134                         45            51                    38          0.0234    134      22       44                    68        0.013        3.66      1.918\~6.985    2.074    1.178\~3.653    2.271   1.600\~3.223
  \[[@r100]\]   2005           401                         111           170                   120         0.00992   266      10       89                    167       0.908        15.448    7.761\~30.746   2.658    1.878\~3.763    3.71    2.884\~4.774
  \[[@r108]\]   2005           193                         81            77                    35          0.101     203      25       89                    89        0.932        8.239     4.544\~14.937   2.2      1.340\~3.613    3.123   2.336\~4.175
  \[[@r3]\]     2006           121                         54            49                    18          0.472     132      22       70                    40        0.651        5.455     2.589\~11.491   1.556    0.800\~3.026    2.43    1.697\~3.480
  \[[@r84]\]    2006           759                         142           349                   268         0.327     594      27       179                   388       0.558        7.614     4.904\~11.822   2.823    2.225\~3.582    2.932   2.459\~3.495
  \[[@r84]\]    2007           361                         88            156                   117         0.0471    328      16       109                   203       0.962        9.543     5.347\~17.030   2.483    1.778\~3.468    3.109   2.453\~3.940
  \[[@r133]\]   2007           693                         135           341                   217         0.999     172      4        57                    111       0.567        17.264    6.223\~47.893   3.06     2.131\~4.395    1.949   1.466\~2.592
  \[[@r133]\]   2007           120                         18            49                    53          0.501     995      43       351                   601       0.654        4.747     2.559\~8.804    1.583    1.050\~2.386    3.384   2.532\~4.523
  \[[@r56]\]    2007           155                         16            66                    73          0.982     151      10       66                    75        0.669        1.644     0.700\~3.859    1.027    0.643\~1.643    1.161   0.821\~1.641
  ??            2007           95                          39            34                    22          0.0398    99       10       50                    39        0.58         6.941     2.898\~16.491   1.205    0.610\~2.380    2.626   1.742\~3.958
  ??            2007           445                         68            182                   195         0.0694    1041     41       308                   692       0.661        5.886     3.872\~8.948    2.097    1.645\~2.673    2.412   2.023\~2.876
  \[[@r128]\]   2007           399                         69            182                   148         0.601     329      12       100                   217       0.994        8.431     4.412\~16.112   2.669    1.935\~3.679    2.883   2.265\~3.670
  \[[@r13]\]    2007           278                         14            120                   144         0.216     557      16       179                   362       0.547        2.2       1.047\~4.623    1.685    1.247\~2.278    1.552   1.221\~1.974
  \[[@r93]\]    2007           87                          19            38                    30          0.578     232      13       60                    159       0.092        7.746     3.459\~17.346   3.357    1.911\~5.896    3.409   2.331\~4.986
  \[[@r83]\]    2008           164                         40            74                    50          0.483     155      10       42                    103       0.108        8.24      3.812\~17.813   3.63     2.185\~6.029    3.54    2.488\~5.038
  Total                        5027                                                                                  5878                                                                                                                       

In our primary analysis, multivariate meta-analysis was conducted to estimate the pooled risk and there was a significantly increased risk of AMD among individuals with both homozygous variant AA genotype (Bayesian random effect *OR*~1~=8.469, 95% *CrI*: 6.766, 10.710) and heterozygous variant AG genotype (Bayesian random effect *OR*~2~=2.243, 95% *CrI*: 1.969, 2.559) of the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism. A moderate level of between-study heterogeneity (*Q*=19.201, p=0.084, *I*^2^=37.5%) was found for the homozygous AA genotype and no between-study heterogeneity (*Q*=13.951, p=0.304, *I*^2^=14.0%) was found for the heterozygous AG genotype. The estimated parameter λ was 0.378 (95% *CrI*: 0.329, 0.428), which suggested a moderate codominant genetic mode of action. When we removed the two studies \[[@r96],[@r97]\] with HW disequilibrium, similar results appeared with the pooled *OR*~1~, *OR*~2~, and λ of 9.257 (95% *CrI*: 7.267, 11.910), 2.334 (95% *CrI*: 2.012, 2.706), and 0.380 (95% *CrI*: 0.327, 0.435), respectively; however, no significant between-study heterogeneity was found for either the homozygous AA genotype (*Q*=13.898, p=0.178, *I*^2^=28.0%) or the heterozygous AG genotype (*Q*=13.041, p=0.221, *I*^2^=23.3%). The pooled estimates also remained similar after adjusting HW disequilibrium by coefficient *F* (*OR*~1~=9.065 \[95% *CrI*: 7.397, 11.180\], *OR*~2~=2.306 \[95% *CrI*: 2.039, 2.607\], and λ=0.379 \[95% *CrI*: 0.332, 0.427\]).

Multivariate meta-analysis also showed that there was a significantly increased risk of AMD among individuals with both the homozygous variant TT genotype (Bayesian random effect *OR*~1~=7.512, 95% *CrI*\\: 5.703, 9.659) and heterozygous variant TG genotype (Bayesian random effect *OR*~2~=2.353, 95% *CrI*: 2.072, 2.665) of the *LOC387715/ ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism. The estimated parameter for λ was 0.426 (95% *CrI*: 0.387, 0.467), which suggested a moderate codominant genetic mode of action.

For the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism, stratification by ethnicity indicated a considerable variation in the size of effects between Asian populations (Bayesian random effect *OR*~1~=7.100, 95% *CrI*: 5.325, 9.494; Bayesian random effect *OR*~2~=2.009, 95% *CrI*: 1.625, 2.511; λ=0.356, 95% *CrI*: 0.267, 0.442) and Caucasian populations (Bayesian random effect *OR*~1~=10.130, 95% *CrI*: 6.323, 0.574; Bayesian random effect *OR*~2~=2.347, 95% *CrI*: 1.918, 2.910; λ=0.368, 95% *CrI*: 0.307, 0.434). A moderate degree of between-study heterogeneity was found for the AA homozygous genotype among both Asians (*Q*=13.978, p=0.030, *I*^2^=57.1%) and Caucasians (*Q*=13.203, p=0.022, *I*^2^=62.1%), but no significant between-study heterogeneity was found for the AG homozygous genotype among either population (Asians: *Q*=7.309, p=0.293, *I*^2^=17.93%; Caucasians: *Q*=5.165, p=0.396, *I*^2^=3.2%). For the *LOC387715/ ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism, a moderate level of between-study heterogeneity was found for the TT homozygous genotype among Caucasians (*Q*=45.035, p=0.000, *I*^2^=73.8%) and for the TG heterozygous genotype among both Asians (*Q*=7.783, p=0.020, *I*^2^=74.5%) and Caucasians (*Q*=29.790, p=0.003, *I*^2^=59.7%); however, no significant degree of between-study heterogeneity was found for the TT homozygous genotype among Asians (*Q*=1.232, p=0.54, *I*^2^=0.0%).

Results of metaregression analysis indicated that classification of AMD (wet AMD versus combined AMD) was significantly associated with log *OR*~2~ (metaregression beta coefficient=-0.325, p=0.016). We performed stratification analysis on wet AMD and the combined AMD of the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism, and found a considerable difference in effects between wet AMD (Bayesian random effect *OR*~1~=10.110, 95% *CrI*: 6.998, 16.490; Bayesian random effect *OR*~2~=2.647, 95% *CrI*: 2.132, 3.280; λ=0.420, 95% *CrI*: 0.0.350, 0.491) and combined AMD (Bayesian random effect *OR*~1~=7.087, 95% *CrI*: 5.284, 9.523; Bayesian random effect *OR*~2~=1.931, 95% *CrI*: 1.643, 2.277; λ=0.337, 95% *CrI*: 0.267, 0.408). This stratification exhibited no between-study heterogeneity for either *OR*~1~ (*Q*=3.232, p=0.664, *I*^2^=0.0%) or *OR*~2~ (*Q*=0.890, p=0.971, *I*^2^=0.0%) for combined AMD, and found a moderate degree of between-study heterogeneity for *OR*~1~ (*Q*=13.978, p=0.030, *I*^2^=57.1%) and non-significant between-study heterogeneity for *OR*~2~ (*Q*=7.309, p=0.293, *I*^2^=17.9%) of the wet AMD ([Table 5](#t5){ref-type="table"}).

###### Age related macular degeneration (AMD): *HTRA1* SNPs versus *ARMS2* single nucleotide polymorphisms (SNPs).

  **Comparison**                                                                                           **No. of studies**          **Total sample size (n)**   **Bayesian random effects**   **Fixed effects**   **Random effects**   **Heterogeneity**                                                  
  -------------------------------------------------------------------------------------------------------- --------------------------- --------------------------- ----------------------------- ------------------- -------------------- ------------------- ------------- --------------- -------- ------- ------
  **Odds ratio**                                                                                           **95% credible interval**   **Odds ratio**              **95% CI**                    **Odds ratio**      **95% CI**           **Q**               **P value**   **I2 (%)**                       
  ***HTRA1* ([rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638))**                                                                                                                                                                                                               
  **A allele versus G allele**                                                                                                                                                                                                                                                                               
  Total                                                                                                    16                          4034/3212                   /                             /                   2.664                2.476, 2.867        2.803         2.486, 3.159    34.576   0.003   56.6
  HWE                                                                                                      14                          3124/2784                   /                             /                   2.754                2.542, 2.984        2.909         2.547, 3.324    30.471   0.004   57.4
  Adjusted HWE                                                                                             16                          4034/3212                   /                             /                   2.701                2.510, 2.907        2.827         2.519, 3.173    31.923   0.007   53
  East Asian                                                                                               7                           835/868                     /                             /                   2.847                2.473, 3.278        2.847         2.473, 3.278    4.873    0.56    0
  Caucasian                                                                                                8                           2970/2160                   /                             /                   2.589                2.366, 2.833        2.8           2.289, 3.424    28.452   0       75.4
  Seven studies with 2 SNPs                                                                                7                           1533/1206                   /                             /                   3.059                2.717, 3.444        3.053         2.681, 3.478    7.028    0.318   14.7
  **AA versus GG**                                                                                                                                                                                                                                                                                           
  Total                                                                                                    16                          4034/3212                   7.972                         6.453, 9.778        7.21                 6.035, 8.614        7.737         6.096, 9.821    24.308   0.06    39.2
  HWE                                                                                                      14                          3124/2784                   8.424                         6.667, 10.540       7.515                6.201, 9.107        8.16          6.314, 10.546   20.51    0.083   37.6
  Adjusted HWE                                                                                             16                          4034/3212                   8.225                         6.700, 10.030       7.423                6.205, 8.880        7.928         6.286, 10.000   22.776   0.089   35.3
  East Asian                                                                                               7                           835/868                     7.604                         5.541, 10.100       7.273                5.390, 9.815        7.273         5.390, 9.815    4.27     0.64    0
  Caucasian                                                                                                8                           2970/2160                   8.691                         5.813, 13.600       7.258                5.719, 9.211        8.687         5.556, 13.582   19.969   0.006   65.8
  Wet AMD                                                                                                  8                           1348/1212                   9.484                         6.834, 12.800       9.205                6.941, 12.207       9.843         6.539, 14.817   14.147   0.049   51.6
  Wet AMD + Dry AMD                                                                                        8                           2686/2000                   6.561                         5.137, 8.270        6.138                4.881, 7.719        6.138         4.881, 7.719    5.391    0.612   0
  Seven studies investigated 2 SNPs                                                                        7                           1533/1206                   8.967                         5.964, 12.920       8.534                6.411, 11.360       9.309         5.924, 14.682   14.097   0.029   58.8
  **AG versus GG**                                                                                                                                                                                                                                                                                           
  Total                                                                                                    16                          4034/3212                   2.226                         1.982, 2.496        2.168                1.944, 2.418        2.18          1.943, 2.447    15.784   0.397   5
  HWE                                                                                                      14                          3124/2784                   2.28                          2.006, 2.589        2.193                1.943, 2.475        2.232         1.935, 2.574    15.295   0.289   15.1
  Adjusted HWE                                                                                             16                          4034/3212                   2.252                         2.011, 2.516        2.192                1.966, 2.445        2.204         1.962, 2.477    15.942   0.386   5.9
  East Asian                                                                                               7                           835/868                     2.277                         1.781, 2.866        2.202                1.684, 2.878        2.219         1.665, 2.957    6.812    0.339   12.3
  Caucasian                                                                                                8                           2970/2160                   2.273                         1.916, 2.741        2.205                1.948, 2.495        2.221         1.949, 2.531    7.453    0.383   6.1
  Wet AMD                                                                                                  8                           1348/1212                   2.692                         2.197, 3.249        2.706                2.231, 3.281        2.708         2.219, 3.305    7.311    0.397   4.3
  Wet AMD + Dry AMD                                                                                        8                           2686/2000                   1.959                         1.723, 2.222        1.953                1.711, 2.230        1.953         1.711, 2.230    1.024    0.994   0
  Seven studies with 2 SNPs                                                                                7                           1533/1206                   2.392                         1.938, 2.907        2.396                2.004, 2.866        2.471         1.946, 3.138    9.387    0.153   36.2
  **λ**                                                                                                                                                                                                                                                                                                      
  Total                                                                                                                                                            0.386                         0.343, 0.430                                                                                                 
  HWE                                                                                                                                                              0.387                         0.340, 0.435                                                                                                 
  Adjusted HWE                                                                                                                                                     0.386                         0.343, 0.429                                                                                                 
  East Asian                                                                                                                                                       0.403                         0.311, 0.491                                                                                                 
  Caucasian                                                                                                                                                        0.381                         0.327, 0.438                                                                                                 
  Wet AMD                                                                                                                                                          0.441                         0.373, 0.510                                                                                                 
  Wet AMD + Dry AMD                                                                                                                                                0.359                         0.300, 0.419                                                                                                 
  Seven studies with 2 SNPs                                                                                                                                        0.4                           0.331, 0.471                                                                                                 
  ***LOC387715/ARMS2* ([rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924))**                                                                                                                                                                                                     
  **T allele versus G allele**                                                                                                                                                                                                                                                                               
  Total                                                                                                    18                          5027/5878                   /                             /                   2.725                2.556, 2.906        2.734         2.366, 3.158    80.195   0       78.8
  HWE                                                                                                      17                          4893/5744                   /                             /                   2.742                2.569, 2.928        2.761         2.376, 3.209    79.116   0       79.8
  Adjusted HWE                                                                                             18                          5027/5878                   /                             /                   2.715                2.547, 2.896        2.719         2.351, 3.145    81.68    0       79.2
  East Asian                                                                                               3                           289/325                     /                             /                   2.692                2.086, 3.315        2.692         2.086, 3.315    0.481    0.786   0
  Caucasian                                                                                                13                          4425/4355                   /                             /                   2.769                2.580, 2.972        2.794         2.333, 3.346    73.265   0       83.6
  Seven studies with 2 SNPs                                                                                7                           1471/1225                   /                             /                   3.276                2.912, 3.686        3.211         2.711, 3.802    11.596   0.072   48.3
  **TT versus GG**                                                                                                                                                                                                                                                                                           
  Total                                                                                                    18                          5027/5878                   7.512                         5.703, 9.659        7.096                6.069, 8.296        7.216         5.492, 9.480    48.208   0       65.3
  HWE                                                                                                      17                          4893/5744                   7.826                         5.886, 10.140       7.394                6.294, 8.683        7.533         5.707, 9.943    43.926   0       64.2
  Adjusted HWE                                                                                             18                          5027/5878                   7.51                          5.692, 9.672        7.1                  6.071, 8.303        7.209         5.483, 9.480    48.331   0       65.4
  East Asian                                                                                               3                           289/325                     /                             /                   6.934                4.206, 11.431       6.934         4.206, 11.431   1.232    0.54    0
  Caucasian                                                                                                13                          4425/4355                   7.57                          5.326, 10.850       7.261                6.076, 8.677        7.41          5.176, 10.607   45.035   0       73.8
  Wet AMD                                                                                                  7                           1029/1073                   8.567                         5.509, 12.600       7.828                5.786, 10.582       8.273         5.191, 13.185   13.738   0.033   56.9
  Wet AMD + Dry AMD                                                                                        11                          3998/4805                   7.021                         4.678, 9.950        6.846                5.703, 8.218        6.708         4.734, 9.505    33.919   0       71.1
  Seven studies with 2 SNPs                                                                                7                           1471/1225                   9.767                         6.169, 14.480       9.134                6.951, 12.002       9.521         5.922, 15.307   17.209   0.009   65.6
  **GT versus GG**                                                                                                                                                                                                                                                                                           
  Total                                                                                                    18                          5027/5878                   2.353                         2.072, 2.665        2.336                2.134, 2.558        2.324         1.993, 2.709    42.812   0.001   60.3
  HWE                                                                                                      17                          4893/5744                   2.38                          2.093, 2.702        2.343                2.138, 2.569        2.336         1.990, 2.741    42.638   0       62.5
  Adjusted HWE                                                                                             18                          5027/5878                   2.334                         2.058, 2.643        2.316                2.115, 2.535        2.29          1.956, 2.681    45.09    0       62.3
  East Asian                                                                                               3                           289/325                     /                             /                   1.843                1.203, 2.823        2.119         0.893, 5.029    7.783    0.02    74.5
  Caucasian                                                                                                13                          4425/4355                   2.424                         2.062, 2.865        2.422                2.198, 2.669        2.445         2.082, 2.871    29.79    0.003   59.7
  Wet AMD                                                                                                  7                           1029/1073                   2.519                         1.983, 3.147        2.531                2.053, 3.122        2.519         1.813, 3.501    13.05    0.042   54
  Wet AMD + Dry AMD                                                                                        11                          3998/4805                   2.285                         1.921, 2.694        2.293                2.074, 2.536        2.253         1.886, 2.691    29.067   0.001   65.6
  Seven studies with 2 SNPs                                                                                7                           1471/1225                   2.507                         1.999, 3.088        2.564                2.137, 3.076        2.567         2.065, 3.191    7.834    0.251   23.4
  **λ**                                                                                                                                                                                                                                                                                                      
  Total                                                                                                                                                            0.426                         0.387, 0.467                                                                                                 
  HWE                                                                                                                                                              0.423                         0.384, 0.463                                                                                                 
  Adjusted HWE                                                                                                                                                     0.422                         0.383, 0.462                                                                                                 
  East Asian                                                                                                                                                       /                             /                                                                                                            
  Caucasian                                                                                                                                                        0.438                         0.395, 0.483                                                                                                 
  Wet AMD                                                                                                                                                          0.433                         0.354, 0.513                                                                                                 
  Wet AMD + Dry AMD                                                                                                                                                0.428                         0.382, 0.475                                                                                                 
  Seven studies with 2 SNPs                                                                                                                                        0.406                         0.341, 0.472                                                                                                 

Summary odds ratios of *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) polymorphism and *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) polymorphism.

We also performed stratification analysis on the wet AMD and combined AMD of the *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism, and found a considerable difference in effect between wet AMD (Bayesian random effect *OR*~1~=8.567, 95% *CrI*: 5.509, 12.600; Bayesian random effect *OR*~2~=2.519, 95% *CrI*: 1.983, 3.147; λ=0.433, 95% *CrI*: 0.354, 0.513) and combined AMD (Bayesian random effect *OR*~1~=7.021, 95% *CrI*: 7.021; Bayesian random effect *OR*~2~=2.285, 95% *CrI*: 1.921, 2.694; λ=0.428, 95% *CrI*: 0.382, 0.475). This stratification found no between-study heterogeneity for either *OR*~1~ (*Q*=5.391, p=0.612, *I*^2^=0.0%) or *OR*~2~ (*Q*=1.024, p=0.994, *I*^2^=0.0%) for combined AMD, and found a moderate degree of between- study heterogeneity for *OR*~1~ (*Q*=14.147, p=0.049, *I*^2^=51.6%) and non-significant between-study heterogeneity for *OR*~2~ (*Q*=7.311, p=0.397, *I*^2^=4.3%) of the wet AMD ([Table 5](#t5){ref-type="table"}).

There was no evidence of small study bias or publication bias for the two comparisons. For the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism, funnel plots for the comparisons made for the AA homozygotes and AG heterozygotes gave corrected p=0.077 (corrected Begg's *z*=1.77) and corrected p=0.669 (corrected Begg's *z*=0.43), respectively. [Figure 4](#f4){ref-type="fig"} shows the cumulative result of meta-analysis of the AA homozygotes and AG heterozygotes; they remained significant and stayed relatively unchanged after the third study ([Figure 4A,B](#f4){ref-type="fig"}). [Figure 5](#f5){ref-type="fig"} shows the cumulative result of meta-analysis of the TT homozygotes and TG heterozygotes of *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) with G→T polymorphism; they remained significant and relatively unchanged after the third study.

![Cumulative random-effects meta-analysis of homozygous (**A**: AA versus GG) and heterozygous (**B**: AG versus GG) genotypes of the *HTRA1* gene [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism and ager related macular degeneration (AMD). For study details, see [Table 3](#t3){ref-type="table"}.](mv-v16-1958-f4){#f4}

![Cumulative random-effects meta-analysis of homozygous (**A**: TT versus GG) and heterozygous (**B**: GT versus GG) genotypes of *LOC387715/ARMS2* gene [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism and age related macular degeneration (AMD). For study details, see [Table 4](#t4){ref-type="table"}.](mv-v16-1958-f5){#f5}

Discussion
==========

To our knowledge, this is the first general overview of the association between the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism, the *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism, and susceptibility to AMD. The results of our meta-analysis suggest a strong association and a moderate codominant genetic mode of action. Our primary analysis shows that, for the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism, the AA homozygotes carry an 8.5 fold increased risk of AMD, and the AG heterozygous variants carry just a 2.5 fold increase in risk when compared with GG homozygotes; for the *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism, the TT homozygotes carry a 7.5 fold increased risk of AMD, and the TG heterozygous variants carry just a 2.4 fold increase in risk when compared with the GG homozygotes. In addition, our allele-based analysis suggests a nearly 3.0-fold increase in susceptibility to AMD among persons with the A allele of the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism and the T allele of the *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism.

Our findings were based on several gene-association studies, which include several thousand participants and were robust in terms of all the planned and performed sensitivity analyses. We found no evidence of publication bias or small study bias by funnel plots and cumulative meta-analysis; moreover, "moderate," "moderate," and "low" degrees of between-study heterogeneity were found in alleles (A versus G), homozygotes (AA versus GG), and heterozygotes (AG versus GG) of the association between the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism and AMD. When HWE was examined, 11 of the 13 studies showed no deviation and two showed some deviation. The removal of the two HW disequilibrium studies meant that our overall results were also robust; statistical adjustment for the deviations were similar and consistent with the incipient results. The point estimate values were closer to a codominant model after removal of the HW disequilibrium studies and statistical adjustment for the deviation; this suggested a multiplicative genetic mode of action that needs to be verified by more studies, particularly large-scale, long-term longitudinal studies. Moderate between-study heterogeneity was also found in the alleles (T versus G), homozygotes (TT versus GG), and heterozygotes (TG versus GG) of the association between the *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism and AMD. However, the data we collected in this systematic review can only support a moderate codominant genetic model with a tight confidence interval.

The *HTRA1* gene encodes a member of the trypsin family of serine proteases \[[@r133]\]. The precise pathomechanism by which the HTRA1 [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) A risk allele affects susceptibility to AMD is still unclear \[[@r134],[@r135]\]. The upregulation of *HTRA1* plays a detrimental role in arthritic disease through its capacity to degrade extracellular matrices (ECMs) directly and to upregulate the expression of matrix metalloproteinase, which results in ECM degradation \[[@r88]\]. Yang et al. \[[@r90]\] hypothesized that the most likely mechanism in the involvement of [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) with AMD may be the enhancement of ECM degradation \[[@r90]\]. As shown in the model of laser-induced CNV \[[@r136]\], the destruction of the Bruch membrane leads to CNV development \[[@r90]\]. Although the function of *HTRA1* in ocular tissues is unclear, it is reasonable to speculate that CNV may develop when the Bruch membrane is exposed to the detrimental effects of *HTRA1*. In vitro, higher luciferase expressions have been reported in both ARPE19 and HeLaS3 cells transfected with the *HTRA1* [rs1120638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) risk homozygote (AA) genotype when compared to the wild-type (GG) \[[@r101]\]. It has been suggested that the presence of the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) A risk allele may alter the affinity of transcription factors, including the adaptor-related protein complex 2 alpha and serum response factor to the *HTRA1* promoter \[[@r101]\]. Another potential mechanism by which the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) A allele may increase AMD risk is its ability to bind to TGF-β family members and to inhibit signaling of TGF-β family proteins, such as bone morphogenetic protein 2 and bone morphogenetic protein 4), which have previously been reported to act as negative growth regulators in RPE \[[@r89],[@r137]\].

Although an association between the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism and AMD was found, Kanda and others \[[@r95]\] considered that the [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism of the *HTRA1* gene did not make a major contribution to regulation of the *HTRA1* gene and there is no association between *HTRA1* G→A polymorphism and AMD. To verify these conclusions, they generated mammalian expression constructs carrying three different lengths of the normal HTRA1 promoter (WT-long, -medium, and -short) and the mutant sequence carrying the AMD-risk allele at the single nucleotide polymorphism (SNP) [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) (SNP-long and -medium), and these constructs were transfected into human embryonic kidney293 (HEK293), human-derived retinal pigment epithelial (ARPE19), and Human retinoblastoma (Y79) cells. As a result, they found that WT and variant SNPs of the *HTRA1* promoter activities did not show significant differences in the luciferase reporter expression, and the WT-short promoter (not including the [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) region) showed higher transcriptional activities than the others. A further quantitative analysis provided no evidence for significant change of mRNA expression between control and AMD retinas. This finding contrasts with the previous original experiment, which suggested an increase in *HTRA1* expression in lymphocytes from AMD patients \[[@r90],[@r127]\]. Taken together, these studies seem to draw a conflicting conclusion to those of the other studies in our meta-analysis.

Localization of the LOC387715/ARMS2 protein to the mitochondrial outer membrane in transfected mammalian cells suggests intriguing mechanisms through which an A69S change may influence AMD susceptibility. Mitochondria are implicated in the pathogenesis of other age-related neurodegenerative diseases, including Alzheimer disease, Parkinson disease, and so on \[[@r138]\]. Mitochondrial dysfunction associated with aging can result in impairment of the energy metabolism and homeostasis, generation of reactive oxygen species, accumulation of somatic mutations in mitochondrial DNA, and activation of the apoptotic pathway \[[@r139]-[@r141]\]. Decreased number and size of mitochondria, loss of cristae, or reduced matrix density are observed in AMD retinas compared with controls, and mitochondrial DNA deletions and cytochrome *c* oxidase-deficient cones accumulate in the aging retina, particularly in the macular region \[[@r140],[@r142]\]. Moreover, mutations in mitochondrial proteins (e.g., dynamin-like guanosine triphosphatase \[GTPase\] optic atrophy 1 \[OPA1\]) are associated with optic neurodegenerative disorders \[[@r143]\]. Photoreceptors and RPE contain high levels of polyunsaturated fatty acids and are exposed to intense light and near-arterial levels of oxygen, providing considerable risk for oxidative damage \[[@r143],[@r144]\]. Kanda and others therefore propose that the altered function of the putative mitochondrial protein LOC387715/ARMS2 by A69S substitution increases the susceptibility to the aging-associated generation of macular photoreceptors \[[@r95]\]. However, they did not observe any significant difference in the expression, stability, or localization of the A69S variant LOC387715/ARMS2 protein in mammalian cells. It is plausible that the A69S alteration modifies the function of the LOC387715/ARMS2 protein by affecting its conformation and/or interaction. For this reason, additional analysis of the LOC387715/ARMS2 protein with Ala or Ser codon 69 and its function in vivo are needed to better understand its contribution to AMD pathogenesis.

Even though the results presented here are contradictory, the A allele of the *HTRA1* gene [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism is reasonably common, with an allele frequency of over 30% in a control population and over 40% in an Asian control population, and the T allele frequency of the *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism was 25.17% in a control population and 38.67% in Asians. This means that the effect at the population level, especially for Asian populations, could be quite important. The proportion of AA and AG genotypes of the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism in a control population is 48% and the pooled OR for these two genotypes is 3.13. These two data were 64.07, 3.47 and 39.81, 3.07 for Asians and Caucasians, respectively. For the *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism, the proportion of TT and GT genotypes in a control population is 38.89% and the pooled *OR* for these two genotypes is 3.05. These two data were 64.00, 3.17 and 35.40, 3.13 for Asians and Caucasians, respectively.

The PAR for the combined genotypes AA and AG of the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism is 56.0% (63.5% for Asians, 48.4% for Caucasians, 61.3% for wet AMD, 51.1% for combined AMD). The PAR for the combined genotypes TT and GT of *LOC387715/ARMS2* gene [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism is 47.9% (55.4% for Asians, 44.1% for Caucasians, 56.8% for wet AMD, 42.4% for combined AMD). In other words, the *HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism is involved in over half of all cases of AMD, quite close to the previous estimate of the first major AMD-susceptibility allele, *CFH* Y402H (58.9%) \[[@r79]\]. The *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism is also involved in nearly half of all AMD cases. Higher PAR can explain part of why both these genes (*HTRA1* [rs11200638](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11200638) G→A polymorphism and *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism) play important roles in AMD, especially for wet AMD populations.

In conclusion, this Human Genome Epidemiology (HuGE) systematic review presents strong evidence for an association between the *HTRA1* rs11200638 G→A polymorphism, *LOC387715/ARMS2* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) G→T polymorphism, and AMD, and suggests that both of these genes play important roles in this disease. Potential gene-gene and gene-environmental interactions and possible mechanisms of AMD are also summarized and discussed. Our findings suggest that these genetic variations may serve as biomarkers enabling the diagnosis of AMD in a more efficient and economical way. However, large-scale, long-term longitudinal studies are required to substantiate and strengthen this association.
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